COO

Business profile & competitive position

The Cooper Companies, Inc. is classified in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. Its operations are split into two segments: CooperVision and CooperSurgical. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses plus specialty eyecare products, including silicone hydrogel lenses, myopia management products, orthokeratology lenses and scleral lenses. CooperSurgical offers more than 600 products and services in fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products are sold in over 130 countries and the company states they positively impact more than fifty million lives each year.

The most differentiated asset in the portfolio is the MiSight 1 day lens, which the company describes as the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. That tri-regulatory approval creates a real, if narrow, moat around a growing myopia-management market. Roughly 500 employees work in research and development across both segments, and the global footprint suggests broad distribution scale.

Still, the profitability numbers temper the narrative of a wide-moat compounder. Net margin is 5.6% and return on equity is just 2.8%. Those figures are modest for a medical-device name. A 2.8% ROE implies the business is either capital-intensive, still digesting acquisition-related capital, or reinvesting heavily in distribution and market development rather than converting sales into high shareholder returns. The 5.6% net margin similarly points to operational scale without premium pricing power across the full portfolio. The moat therefore appears selective: strong in MiSight and in CooperSurgical’s integrated fertility/women’s health model, but not uniformly high-return across all product lines.

Financial posture

At a market capitalization of $13.6 billion and a trailing P/E of 59.0, COO is priced at a substantial premium to its current earnings power. A P/E near 60x paired with a 5.6% net margin and 2.8% ROE is a demanding combination. The valuation implies that investors are underwriting a significant acceleration in profitability, successful commercialization of newer products, or both. Alternatively, the multiple may reflect scarcity value attached to the myopia-management and fertility franchises, though the income-statement evidence for that premium is not yet reflected in margins.

The stock’s beta is 0.82, meaning it has historically moved less than the broad market, consistent with the defensive Healthcare classification. The current share price is $69.59, with a 50-day exponential moving average of $71.82, so price is sitting slightly below its intermediate-term moving average. The relative strength index is 37.3, just inside the lower half of the range and approaching traditionally oversold territory. None of these figures are directional signals on their own, but together they describe a stock that has softened recently despite a string of earnings beats.

Strategic priorities & outlook

The company’s most recent 10-K filing lays out four operational priorities that investors can use to evaluate management execution.

First, CooperVision is focused on greater worldwide market penetration of recently introduced products and on expanding its presence in existing and emerging markets. This is a volume-and-distribution story rather than a pricing story. Second, CooperVision is increasing investment in distribution and packaging capabilities to support business growth and quality service, which aligns with the capital intensity implied by the low ROE. Third, CooperVision is investing to develop the myopia-management market by educating eye-care practitioners, patients and families, a direct bet on the MiSight 1 day opportunity. Fourth, CooperSurgical expects to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health.

These priorities suggest the company is not in harvest mode. It is building infrastructure, educating markets, and actively looking for M&A in fertility and women’s health. That posture helps explain why current returns are subdued, but it also means the investment thesis depends on management’s ability to convert spending into durable revenue and eventually margin expansion.

Macro & geopolitical exposure

As a Healthcare / Medical – Instruments & Supplies company, COO is exposed to a well-defined set of macro and geopolitical factors. Regulatory clearance and compliance are central: contact lenses, surgical devices, fertility products and genomic/cryopreservation services are governed by agencies such as the FDA and equivalent foreign regulators in China, Japan, the EU and elsewhere. Approvals can create market opportunities when obtained, but delays, label changes or adverse regulatory actions can reshape demand.

Trade policy and currency also matter. With sales in over 130 countries, foreign-exchange movements affect translated revenue and margin, while tariffs or duties on polymer resins, packaging materials, lens components and finished-device shipments can influence cost structure. Supply-chain resilience is another standard industry concern: medical-device manufacturers rely on specialized materials and packaging, and disruptions can affect service quality and inventory. Broader macro trends such as reimbursement policies, payer budgets, demographics and fertility rates are relevant background variables for both CooperVision and CooperSurgical demand, even if they manifest slowly.

Recent developments

The most directly relevant recent headline is a September 3, 2026 Zacks article titled “Countdown to The Cooper Companies (COO) Q3 Earnings: Wall Street Forecasts for Key Metrics,” which appeared two trading days before the company’s scheduled September 9, 2026 after-the-close report. The same news feed also carried unrelated items around the COO ticker: on September 2, 2026, GuruFocus published Dell Technologies’ Q2 2026 earnings-call highlights; on August 28, 2026, The Motley Fool reported that Unity Software COO Alexander Blum sold 22,559 shares for $1 million; and on August 23, 2026, The Motley Fool covered a Rigetti Computing COO share sale. Those three stories involve other companies’ executives or other tickers, not The Cooper Companies’ business operations, but they illustrate the type of headline noise that can surround a ticker during an earnings window.

Earnings behavior & post-earnings drift

COO has delivered an unblemished beat record over the last eight reported quarters, with a 100% beat rate and an average earnings surprise of 4.6%. The most recent quarterly results reinforce the pattern. On June 4, 2026, the company reported actual EPS of $1.21 against an estimate of $1.10, a 10.0% surprise, and the stock rose 8.58% the next day and 8.85% over the following five days. On March 5, 2026, actual EPS of $1.10 beat the $1.03 estimate by 6.8%, yet the stock fell 4.55% the next day and 10.82% over the following five days. On December 4, 2025, actual EPS of $1.15 beat the $1.11 estimate by 3.6%, and the stock gained 5.67% the next day and 6.59% over five days. On August 27, 2025, actual EPS of $1.10 beat the $1.07 estimate by 2.8%, but the stock dropped 12.86% the next day and 8.24% over the following five days.

That combination of consistent beats and violent two-way volatility produces a counterintuitive average 5-day post-earnings drift of -0.91%, classified as “down.” The conclusion is not that beats are ignored; rather, the upside from beating has already been partly priced in, and when guidance or qualitative commentary disappoints, the penalty is severe. The next scheduled report is September 9, 2026 after the close, with a consensus EPS estimate of $1.12. Traders watching the release should focus as much on forward commentary and margin guidance as on whether the company beats the $1.12 figure.

For a deeper dive into institutional positioning, analyst rating distribution, and forward estimates heading into the September 9 report, see the full institutional verdict on COO.